The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GYRE | -33.62% | +9.05% | +1.75% | +15% |
| S&P | +13% | +86.41% | +13.26% | +61% |
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The company was founded on March 7, 1997 and is headquartered in San Diego, CA.
No news articles found for Gyre Therapeutics.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $30.56M | 19.9% |
| Gross Profit | $28.94M | 18.0% |
| Gross Margin | 94.67% | -1.6% |
| Market Cap | $677.57M | -42.2% |
| Market Cap / Employee | $135.51M | 0.0% |
| Employees | 5 | 0.0% |
| Net Income | $5.94M | 107.8% |
| EBITDA | $7.58M | 61.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $40.40M | 154.6% |
| Accounts Receivable | $26.57M | 36.3% |
| Inventory | 8.9 | 38.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.54M | -51.0% |
| Short Term Debt | $0.63M | -9.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 4.67% | 0.0% |
| Return On Invested Capital | -90.15% | 19.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $4.32M | 339.8% |
| Operating Free Cash Flow | $4.99M | 197.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 103.42 | 161.17 | 450.92 | 195.80 | - |
| Price to Book | 16.43 | 10.52 | 9.46 | 7.36 | -56.75% |
| Price to Sales | 9.83 | 7.82 | 7.39 | 7.23 | - |
| Price to Tangible Book Value | 16.47 | 10.57 | 10.22 | 7.78 | -54.42% |
| Price to Free Cash Flow TTM | 744.36 | - | |||
| Enterprise Value to EBITDA | 925.96 | 283.15 | 262.82 | 99.31 | -57.14% |
| Free Cash Flow Yield | 0.1% | - | |||
| Return on Equity | 11.6% | 5.5% | 8.1% | - | |
| Total Debt | $1.60M | $1.59M | $1.39M | $1.17M | -35.10% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
